INTRODUCTION
In the past two decades, there has been unprecedented activity in the discovery and development of new antimicrobial agents. One need only reflect upon the long list of new penicillins, cephalosporins, and quinolones that were not available in 1965 to form the opinion that such activity was the result of unrelated research and discovery efforts in many different chemical areas. A closer review of the events surrounding the evolution of antibiotic development, however, suggests a much more orchestrated series of events in which the development of several of the different structural classes of compounds was closely interdependent. Technical advances in penicillin chemistry, for example, helped to push the subsequent rapid development of cephalosporins and other beta-lactams. Advances in understanding of bacterial physiology led to development of structure-activity relationships (SAR) used to direct the chemical modification of antibiotics to improve their antibacterial activity. This approach also led to the discovery of new antibiotics that were active against bacteria that had acquired resistance to the older agents.
The development process for a new antibiotic involves studies that characterize its mechanism of action and extensively assess its safety and efficacy in both humans and other animals. This process can take over 8 years to complete and represents a sizable investment on the part of the sponsoring pharmaceutical company (162) . Given this investment and the current competitive environment with many new agents being marketed, it is incumbent upon the pharmaceutical industry to find new agents that demonstrate distinct advantages over existing antibiotic therapies. This review will discuss some experimental aspects of new antibiotic discovery and describe the various developmental stages through which a new agent must pass to reach the marketplace. An historical perspective on past research efforts in the most prominent antibiotic classes will also be given, to provide insight into the many factors that have influenced the development of these agents.
PRECLINICAL TESTING STAGES Discovery of New Antibiotics
The novel lead structures that have generated most new classes of antibiotics have been found by testing natural products. A number of these novel discoveries are listed in Table 1 and include penicillins, cephalosporins, cephamycins, aminoglycosides, clavulanic acid, glycopeptides, tetracycline, chloramphenicol, carbapenems, and monobactams. The discovery and isolation of the lead structures for each of these classes have provided a unique starting point for chemical modification in attempts to improve their spectrum, pharmacokinetics, and human safety. Three basic approaches have been used to find new antibiotics from natural sources: (i) direct isolation from soil and marine microorganisms, (ii) genetic modification of known antibiotic-producing organisms to induce their production of novel metabolites, and (iii) diversion of natural metabolic pathways of antibiotic-producing organisms by introduction of substrate precursors into the fermentation system (150) .
The sophistication of these approaches has evolved in industry over the years; the first methods for testing fermentation broths prepared from soil samples relied on the detection of antibacterial activity in agar diffusion plates seeded with susceptible target organisms (87, 120) . The specificity of this approach was increased by testing broths with isogenic strain pairs that differed only by their degree of susceptibility to a specific class of antimicrobial agent. Even with such improvements, the isolation of minute amounts of a potentially novel activity from complex fermentation broths involved a heroic effort, using large-scale fermentation methods and multiple chromatographic separations and biological assays to follow the antibiotic activity (120) . Such fermentation discovery efforts initially rely on testing large numbers of soil samples by rapid, automated techniques. One early study, for instance, estimated that, of 21,830 fermentation cultures tested, 6,464 produced antibiotics, 490 of which possessed activities of interest; 6 were eventually submitted for structural determinations, from which two novel structures were isolated (178) (120) . The majority of these new antibiotics isolated from fermentations have come from soil organisms of the genus Streptomyces, although in more recent efforts novel monobactams have been found in fermentations of Agrobacterium and Pseudomonas species (15, 150, 173) .
Continued refinement of the process of antibiotic discovery from natural products has substituted biochemical-based assays for those that rely on killing of the bacterial target organism (120) . The more specific assays have utilized enzyme-linked immunosorbent techniques (179) , beta-lactamase induction (161) , D,D-carboxypeptidase inhibition (143) , receptor ligand binding competition (127) , and monitoring of the specific morphological changes in cells that are characteristically associated with exposure to a particular class of antimicrobial agent (111) . Several novel monobactams were first detected in bacterial fermentations by making use of their inherent property to induce beta-lactamase production in Bacillus licheniformis ATCC 14580 (161) . When the hydrolysis of a chromogenic cephalosporin substrate was measured to detect induced levels of beta-lactamase, nanogram quantities of novel beta-lactams could be detected in fermentation samples (161) . Extreme sensitivity has also been achieved with enzyme-linked immunosorbent assay methods, as described for the detection of novel aminoglycosides (179) . In one typical system, an antibody with specificity for gentamicin was developed and used to coat the surface of a microdilution plate well. A gentamicin-alkaline phosphatase conjugate was then added to the plate, which was subsequently incubated before addition of substrate for alkaline phosphatase, p-nitrophenylphosphate (179) . Competitive assays were run with fermentation broths potentially containing novel aminoglycosides. Following exposure to these broths, the amount of the original enzyme conjugate bound to the antibody in the well was quantitated by measuring the change in absorbance after addition of the enzyme substrate. Such assays are specific for a particular class of antimicrobial agent (in this case, aminoglycosides) and have been reported to be far more sensitive for detecting the presence of antibiotics than conventional plate diffusion assays that measure bacterial growth inhibition (179) . The state of the art in natural product screening techniques for antibiotics is limited only by the ingenuity of the researcher.
Once activities are detected, their chemical source must be identified from a fermentation broth that might contain dozens of commonly known antimicrobial agents and only picogram to microgram amounts of a new agent. The numerous chemical procedures used to isolate novel antibiotics from fermentations include solvent extractions, ion-exchange methods, gel filtration, and adsorption and partition chromatographies (14) . A complete isolation, together with the final structural assignment of the new molecule by nuclear magnetic resonance or X-ray crystallography, can take several months to complete. Given the complexity of isolating novel antibiotics from natural products, it is easy to understand why even more compounds have not been discovered from this source.
A more contemporary approach to natural product research aimed at finding new antibiotics involves the use of recombinant DNA technology for isolating genes involved with antibiotic production. As reviewed by Hunter and Baumberg (79) , cloning of genes from streptomycetes and filamentous fungi has enabled the isolation and characterization of specific genes for several metabolic pathways involved with antibiotic production in these organisms. The isolation of these genes not only enables studies to understand better the pathways for antibiotic production, but also provides the opportunity to mix DNA isolated from different organisms and to transfer it into a new host cell in attempts to stimulate the production of structurally novel antibiotics (79) . Efforts to obtain such genetic recombination between species was greatly facilitated by cloning antibiotic-producing genes on plasmids that could be readily transformed and maintained in recipient fungi (78, 97, 100) . McAlpine et al. (100) used this strategy to transfer DNA from Saccharopolyspora antibiotics, which produced the macrolide oleandomycin, to an S. erythraea mutant that was blocked for production of erythromycin. This cross species mixture of DNA resulted in the production of a structurally novel antibiotic, 2-norerythromycin (100) . The result of such recombinant DNA studies has been the production of antibiotics containing minor structural modifications of known agents. The commercial application of this technology may depend on devising genetic constructs that would produce more novel compounds with greater structural diversity (79 One of the clearest examples of the important relationship between antibiotic structure and biological activity is in the development of cefoxitin from cephamycin C. In 1972, when cephamycins A, B, and C were discovered in fermentation mixtures (154) , few antibiotics were available with activity against gram-negative bacilli that produced large amounts of beta-lactamase. The most active component of the cephamycin mixture was cephamycin C, which possessed activity predominantly against gram-negative bacteria. Its structure ( Fig. 1 ) differs from the classical cephalosporin nucleus by the presence of a methoxy group in the 7-alpha position which conferred on the molecule resistance to hydrolysis by beta-lactamases (152) . Compared with the cephalosporin cephalothin, this stability led to potent in vitro activity against isolates of Escherichia coli, Klebsiella pneumoniae, and indole-positive Proteus sp. A major effort was begun at Merck Sharp & Dohme to make chemical substitutions on the cephamycin C molecule to increase its activity against enteric organisms further and to broaden its spectrum of activity to include gram-positive pathogens. The chemical properties inherent in the cephamycin nucleus made such substitution difficult as compared with earlier efforts accomplished in the cephalosporin class (152) . New chemical reactions were designed to permit side chain substitution, however, and a large number of analogs were made with substitutions at positions C-3 and C-7 (20) of the nucleus. One of these analogs, cefoxitin, contained a thienyl acetyl group at C-7 in place of the alpha-amino-adipic acid moiety of cephamycin C (Fig. 1) . This substitution broadened the spectrum of cefoxitin compared with cephamycin C to include gram-positive organisms and also increased its activity against gram-negative organisms severalfold (11, 152 (152) . The natural methoxy moiety, however, conferred the greatest degree of stability without adversely affecting antibacterial activity, and it has been hypothesized that substitution at this position sterically blocks the beta-lactam bond from attack by the enzyme (11, 152) . Other lines of research established that the carbamoyl moiety at C-3 increases the metabolic stability of cefoxitin in vivo (11 cules, and this effect was associated with a decreased affinity of the substituted analogs for several of the lethal penicillinbinding proteins (PBPs) in gram-negative bacteria (32) .
The result of such structure-activity studies with cefoxitin illustrate how making changes in an active molecule can translate into major clinical benefits such as lower susceptibility to inactivation. The broad spectrum and beta-lactamase stability of cefoxitin constituted a major breakthrough at the time of its discovery, and its availability was a major advance in the treatment of infections caused by organisms that produce high levels of beta-lactamase.
As the SAR around cefoxitin helped to explain its stability to beta-lactamase, similar approaches were taken with monobactams isolated from natural products to improve their antibacterial activity. Monobactams have been isolated from fermentations of several bacterial species, and all contain a 2-azetidinone-1-sulfonic acid moiety (Fig. 2) (60, 156) . The cephalothin homolog had the same spectrum as cephalothin but was less potent, while the cefoperazone homolog was very similar in potency to cefoperazone against gram-negative organisms (60) . These patterns of activity generally followed the affinities of each agent for the lethal PBPs in gram-positive and gram-negative organisms (60) . Some of the best activity against gram-negative organisms was obtained by adding the aminothiazole oxime side chain (Fig. 2) derived from expanded-spectrum cephalosporins and through addition of a methyl group at position 4, which greatly increased stability to beta-lactamase hydrolysis (156) . Several hundred monobactam derivatives were prepared, which led to the properties found in aztreonam (Fig.   2 ). The high activity of aztreonam against gram-negative organisms can be explained by the presence of the aminothiazole oxime moiety, which confers high affinity for the lethal PBPs 3 and la (60, 157) . The presence of a carboxylic acid function on the oxime side chain was shown to improve activity against Pseudomonas aeruginosa (158) . The oxmethyl group at position 4 increases the stability of the beta-lactam ring to hydrolysis by beta-lactamase (156) . In fact, aztreonam is reported to be a potent inhibitor of many type I cephalosporinases that hydrolyze cephalosporins (19) . Aztreonam is also a poor inducer of these beta-lactamases (158) , although some mutants that are overproducers of type I enzyme are resistant to the drug.
Thus, it can be seen that the use of in vitro PBP and beta-lactamase biochemical assays helped to develop the SAR that led to the discovery of aztreonam. The use of these types of specific, mechanism-based assays has helped pharmaceutical researchers develop other novel antibiotics that possess properties that have translated into significant clinical benefits. SAR have also been developed for studying parameters other than antibacterial activity. These include increasing the metabolic stability of compounds in vivo and improving the pharmacokinetics of antibiotics as measured by their distribution characteristics in animals. A number of animal models have been developed to perform these tests.
Animal Models for Studying the Pharmacokinetics and Efficacy of Antibiotics As mentioned previously, mechanism-based studies are frequently used in antibiotic research to guide the SAR which defines those biological characteristics that make a compound effective against a broad range of bacterial pathogens. In vitro activity, however, does not guarantee in vivo efficacy. All new antibiotic compounds with an interesting antibacterial spectrum must be tested in standard animal models to assess their safety, distribution in various tissues (pharmacokinetics), and efficacy against experimental bacterial infections. Since these studies are the final assessment before testing a new compound in humans, a major issue that has confronted pharmaceutical researchers is to understand how well test results in animals predict the performance of the antimicrobial agent in humans. This question can perhaps be answered best by considering some standard methods for performing and evaluating pharmacokinetic studies of antibiotics in animals.
A number of sources provide details on the standard methodologies for performing pharmacokinetic and metabolic studies with experimental antimicrobial agents in animals (63, 104, 149) . While the parameters measured and the methods used in animal studies are similar for all classes of antibiotics, each experimental compound can present special problems with respect to its chemical stability, solubility limitations, toleration by animals, and ease of quantitation in body fluids. At an early stage of testing, when supply of experimental compound may be limiting, the first animal studies ensure that the compound is not rapidly metabolized in vivo and that it is well tolerated. Administering antibiotics in rodents via the intravenous, subcutaneous, or oral route is usually the simplest way to determine the preliminary pharmacokinetics and safety of experimental compounds. It should be emphasized that in each case appropriate control antibiotics must be run for comparison. The best controls to use are those for which extensive published data are available in both test animals and humans (149) . Usually 8 to 12 mice or rats are used per administration route per dose, and the dose ranges selected reflect the anticipated use levels of the agent in clinical trials in humans. As an example, a cephalosporin that will be given in 1-g doses by the intravenous route to a 70-kg adult would be tested in rodents at around 14 to 20 mg/kg by injection into the tail vein. Strict adherence to protocol is an important part of obtaining reproducible animal pharmacokinetic data, since blood samples must be taken from all subjects at precise intervals, usually 15, 30, 60, 90, 120, and 150 min after dosing (149) . Rodents are usually bled through the orbital sinus, and serum or plasma samples are prepared to test for antibiotic. Biological assays which rely on the diffusion of test antibiotic into a confluent lawn of a susceptible test organism grown on an agar plate are usually the simplest ways of measuring antibiotic levels in body fluids (145) . With this method, the test agent must incubate overnight in the assay plate, and this can be problematic if stability data for the experimental compound are not available. The current trend is to assay the level of drug in test samples immediately after collection or following storage at -70TC. Analytical chemical methods such as high-pressure liquid chromatography are now used to quantitate drug levels in body fluids since the assay time is short (73) . This method of analysis is also important for identifying metabolites of the parent compound excreted in urine. This is important since metabolites are often inactive in microbiological assays, yet they must be identified for safety evaluation purposes.
When the mean plasma drug levels determined for each time point are plotted against sampling time, a pharmacokinetic curve is generated from which important information can be obtained (149) . The peak drug concentration (Cmax), time to Cmax (Tmax; particularly relevant for drugs given orally), elimination half-life (tl/23), and area under the plasma concentration-versus-time curve (AUC) are all parameters that can be compared with control compounds tested in a given animal species. As an experimental antimicrobial agent is evaluated further, pharmacokinetic studies are carried out in additional species, usually including beagle dogs and monkeys. The goal of such studies is to obtain multiple pharmacokinetic "models" with which to compare the experimental drug with data obtained from well-characterized antimicrobial agents belonging to the same structural class. More advanced studies are performed on compounds of developmental interest to identify clinically relevant characteristics that would distinguish the compound from existing therapeutic agents. An example of such animal studies involved experiments performed in mice, rats, dogs, and cynomolgus monkeys with a new macrolide antibiotic, azithromycin (65) . These pharmacokinetic models indicated that azithromycin possesses a very long elimination half-life in vivo and achieves high tissue levels compared with the macrolide erythromycin (65) . Additional studies with azithromycin in mice have characterized the extensive accumulation of this compound inside phagocytic cells that are involved with the resolution of experimentally induced infections (66) . These tissue distribution studies define some potential advantages of azithromycin over the standard macrolide, erythromycin, and help with the design of clinical trials in humans (65) . Among numerous other animal pharmacokinetic studies that have evaluated new antibiotics are studies to measure the penetration of azole antifungal compounds into the eyes of rabbits (139), models to study drug penetration into surgical wounds of dogs (133) , and novel sampling methods to measure spinal fluid levels of antibiotics in rats (103) .
One of the most frequent uses of animal models is in making pharmacokinetic predictions of an experimental antibiotic in humans. This is extremely important since new and efficacious antibiotics with long elimination half-lives can be administered less frequently and are therefore more convenient and cost effective to use. In one published study, the long-acting cephalosporin ceftriaxone was administered for surgical and ambulatory use in 42 patients with osteomyelitis (48) . Since ceftriaxone can be given once a day by intramuscular injection, patients can leave the hospital once postsurgical improvement is seen, receiving the remainder of their therapy at home. The use of this long-acting antimicrobial agent resulted in an estimated savings of $204,340 in hospital room costs alone (48) . Efforts to find such longacting agents from research and development programs present a dilemma. It simply is not cost effective to test all interesting new antibiotics in human clinical trials to determine whether they have significant pharmacokinetic advantages over existing agents.
To approach this problem, investigators have developed mathematical models for predicting various pharmacokinetic parameters in humans from data collected for antibiotics tested in a single animal species (16, 140) . This approach VOL. 3, 1990 I e on January 18, 2018 by guest http://cmr.asm.org/ Downloaded from CLIN. MICROBIOL. REV. (Fig. 3A) relies on analyzing data collected for several structurally related antibiotics in a single animal species (140) . For example, by including many cephalosporins that have been tested in both humans and other animals in the analysis, a mathematical relationship can be made between monkey (in this case) and humans for individual pharmacokinetic parameters such as elimination half-life. When the animal model is found that generates the best data "fit," the half-life of experimental agents can be predicted for humans from data obtained in the animal model.
Another approach often used to predict the pharmacokinetics of a new agent in humans makes use of a mathematical procedure for "scaling" data obtained in several different animal species (39, 110) . While small mammals tend to eliminate drugs more rapidly than large mammals, pharmacokinetic data can be mathematically compared between species as a function of body weight (110) . This process is referred to as allometric analysis of pharmacokinetic scaling and has been used to compare the data obtained with antibiotics in humans and other animals (Fig. 3B) . While allometric analysis has been successfully used for predicting the elimination half-lives of new beta-lactams in humans from animal data (26, 109) , it appeared to be insufficiently precise for making such predictions with macrolides (42) . Despite potential limitations, this approach holds an important place in discovery research.
Animal models have also been used to study the metabolism of new antimicrobial agents, as illustrated by the example of imipenem. After the initial clinical testing of this carbapenem antibiotic in humans, it became apparent that the urinary recovery of intact imipenem varied considerably between subjects, ranging from 6 to 33% (86) . Despite this variability, the plasma elimination half-life of the drug in all subjects was around 60 min, and it was calculated that its renal clearance rate was only a fraction of the known rate of human glomerular filtration (86) . These findings, supported by additional metabolic studies, suggested that imipenem was metabolized to a high degree in the human kidney. Similar results obtained in animal studies led to the finding that the enzyme renal dehydropeptidase I, located in the brush border of the renal tubule, was responsible for the high degree of renal metabolism of imipenem in both humans and other animals. For reasons that are still not completely understood, some humans are high metabolizers of imipenem, while others destroy it to a lesser degree in the kidney. The low urinary recovery and metabolic instability of imipenem in the kidney were of clinical concern with respect to achieving optimal therapeutic levels of drug in urine (86) . For this reason, a program was started at Merck Sharp & Dohme to synthesize compounds containing the dehydropeptide bond that might act as inhibitors of renal dehydropeptidase I in vivo and could therefore be coadministered with imipenem. Many analogs were tested and found to be competitive inhibitors of the human enzyme in vitro. This approach addressed only part of the problem, however, since a potent inhibitor of renal dehydropeptidase I would still have to match the pharmacokinetic characteristics of imipenem to be effective in humans. In considering this issue, it was determined that the chimpanzee most closely parallels humans with respect to its metabolism of imipenem. An integral part of the program, then, was to find the most potent dehydropeptidase I inhibitors and attempt to modify them chemically so that they would have a pharmacokinetic profile similar to that of imipenem, as assessed experimentally in the chimpanzee (86 More complex animal protection experiments are designed to test the efficacy of new antimicrobial agents for clearing infecting organisms from specific tissues. Infection models that represent abscess formation, pneumonia, pyelonephritis, meningitis, osteomyelitis, and endocarditis have been developed in mice, rats, and rabbits (27, 58, 62, 105) . Furthermore, with the increased incidence of immunosuppressed patients seen in hospitals today, there is a major need for new antimicrobial agents that provide adequate therapy in patients lacking an intact immune system (57, 98, 134) . Therefore, new infection models have been developed in immunosuppressed animals that measure the efficacy of antimicrobial agents against bacterial and fungal pathogens found in immunosuppressed patients (6, 91, 132) . Usually, the animals are chemically immunosuppressed with repeated doses of agents such as dexamethasone or cyclophosphamide before challenge with a lethal inoculum of test organism (91, 132) . The antimicrobial treatment period for such infection models may be longer than the routine PD50 experiments, since many infections in immunosuppressed patients are chronic in nature and require treatment over a period of time longer than 48 h. Chronic protection studies of this type often require different criteria for measuring successful therapy compared with routine PD50 studies that usually record lethality. These criteria can include counting viable microbial cells in one or more infected organs of animals sacrificed during, or at the completion of, a course of therapy (91) . Measurement of microbial cell clearance from infected tissues is another way of assessing how well a test antibiotic might work in many of the serious infections encountered in humans.
To this point, a number of approaches have been described that aid in the discovery and early characterization of new antibiotics. Obviously, the process for discovering a new antibiotic with advantages over existing therapies can take years, with no guarantee of success. Once such a candidate is identified, however, a recommendation for development document is written which comprehensively reviews all of the in vitro and in vivo data generated and includes a plan for testing the safety of the compound in animals and clinical efficacy in humans. This document is reviewed internally by the pharmaceutical sponsor to determine whether the perceived advantages of the compound are sufficient to warrant the time and expense necessary for its clinical development. Before a new antibiotic can be tested in humans, however, it must first pass an extensive series of safety evaluations in other animals.
Safety Studies in Animals
In his discussion of the early history of cephalosporins, E. P. Abraham recounted that Giuseppi Brotzu, the discoverer of cephalosporin C activity in a fungus, "appeared to have dispensed with toxicity experiments in animals" and tested culture filtrates of the producing organism directly in infectious skin lesions in humans (1) . He subsequently made a crude extract of filtrate and "boldly injected it intramuscularly and intravenously into patients with brucellosis, paratyphoid infections, and typhoid fever" (1) (4) .
In addition to these standard acute and chronic toxicology tests, a number of other safety studies may be required that assess whether the drug has any unusual effects in vivo that can be detected in a battery of general pharmacology tests or in laboratory experiments that may be specific for a given class of antibiotics. With quinolones, for example, tests that measure their effects on developing joint cartilage in young dogs, central nervous system and ocular toxicity in adult dogs, and mutagenicity in both cell culture and animals are usually required (25, 76, 80, 99) . Other examples of supportive drug safety tests include in vivo immediate hypersensitivity tests for beta-lactams and tests evaluating the nephrotoxicity of aminoglycosides (126, 141) .
The successful completion of a series of safety studies on an antibiotic candidate fulfills part of the criteria necessary to allow its clinical testing in humans. At this point, the sponsoring pharmaceutical group is required to compile all data on the compound pertaining to antibacterial spectrum, mechanism of action, experimental efficacy, and safety into a document termed the investigational new drug filing. The various studies included in this document can, in some instances, take up to two years to complete. The investigational new drug filing, in addition to being a comprehensive review of the new antimicrobial agent, also outlines the initial clinical plans to assess its safety and pharmacokinetics in healthy human volunteers. Once such a filing is submitted, the FDA has 30 days to review and approve it before such clinical trials can take place. The investigational new drug filing further serves as the reference document for the outside clinical investigators chosen to study the drug in humans.
CLINICAL TESTING PHASES
The three clinical testing phases required for a new antibiotic are designed to assess its efficacy and safety. A fourth phase can also be delineated, and such clinical tests are conducted to characterize the antimicrobial agent more fully after it has been introduced into the market. The total cost of discovering and developing a new antibiotic can approach 100 million dollars, with 60% of this cost resulting from safety and clinical studies (162) . The phase I to III clinical trials take 5 years to complete on average and involve thousands of subjects (64) (Fig. 5) . As discussed in a recent review (64) , the rules governing the execution of phase I to III antibiotic trials were defined initially in two publications compiled by the FDA in 1977 (52, 53 cephalosporin with a long elimination half-life, which is highly bound to plasma proteins. At high doses of ceftriaxone, the percentage of unbound drug increases and is therefore subject to more rapid elimination from the body by glomerular filtration in the kidney, thereby decreasing the overall elimination half-life (121) . The pharmacokinetic data generated from phase I studies help to set the appropriate dosing schedule for subsequent clinical trials that will evaluate the efficacy of a new antibiotic. The phase I trials may eventually involve several hundred subjects and take as long as 2 years to complete (64) . The data generated on a new antibiotic are carefully reviewed at this point, since subsequent efficacy trials aimed at gaining FDA approval for the drug are costly and can take over 5 years to complete. It is not unusual, therefore, for a candidate to be discontinued should the pharmacokinetic or safety data obtained in phase I trials be less than that desired to encourage further development.
Phase II trials begin to assess the efficacy of a new antibacterial agent in treating patients with diagnosed bacterial infections. The FDA guidelines suggest that each new agent be directly compared with an antimicrobial agent with an established efficacy record for the particular therapeutic indications in question (53, 64) . There is provision, however, for running noncomparative trials for those indications when the degree of efficacy observed with standard agents is well established (64 (64) .
The most meaningful clinical data are obtained from randomized, double-blind, comparative trials in which the performance of the new agent can be evaluated against the standard therapy (64) . Since all modern antibiotics demonstrate a high degree of efficacy in humans, other exploitable characteristics of new compounds are frequently considered in clinical trials. These include demonstration of an improved side effect profile, reduced dosing frequency, or reduced cost over existing therapies. In this regard, comparative trials of imipenem versus gentamicin plus clindamycin, for example, have proven the advantage of the single antimicrobial agent over the standard combination used clinically (142) . Thus, the recent trend towards development of antibiotics with broad spectrum or long half-life makes single-agent therapy and reduced dosing frequency new parameters to consider in comparative clinical studies that have traditionally compared efficacy only.
The importance of phase III studies in demonstrating the advantages of a new antimicrobial agent cannot be overemphasized. While it is common practice to conduct many small clinical trials throughout the world, this tradition presents a problem of data interpretation, since in some instances the number of patients evaluated for a given clinical indication is too small to provide convincing proof of a clinical advantage over existing therapy. It has been suggested that results from these many small studies be combined into a multicenter collaborative study format, in which a larger number of clinical cases per indication can be evaluated in a more significant manner (64) . This is impor-VOL. 3, 1990 on January 18, 2018 by guest http://cmr.asm.org/ Downloaded from CLIN. MICROBIOL. REV. tant to the pharmaceutical sponsor because clinical trials can take several years to complete and cost tens of millions of dollars. The magnitude of this investment can be appreciated from the developmental time line presented in Fig. 5 . This time line can be compared against the traditional 17-year patent life granted to a new compound, which guarantees the pharmaceutical sponsor sole marketing rights to the product. It is easy to see that much of this exclusive lifetime can be consumed by developmental periods during which no income from the new agent is generated.
After completion of the phase II and III studies, the sponsoring pharmaceutical company must organize all of the case report data in preparation for filing these results with the FDA. No predetermined number of studies must be run to qualify a new antibiotic for FDA approval, and the decision to submit a new drug application is based on whether the sponsor, outside clinical investigators, and the FDA agree that a convincing body of safety and efficacy data has been compiled to warrant approval for the indications sought (64) . Once this point is reached, a new drug application is compiled and all data must be reviewed by the FDA, a process that takes an average of 21 months for a new antibiotic (54) . An effort has been made by the FDA to shorten the development time of new therapeutic agents, including antibiotics. In a published revision of the rules and regulations governing development, the FDA has suggested ways for the pharmaceutical sponsor to prepare and submit higher-quality new drug applications and improve the efficiency with which the FDA reviews them (180) .
After approval of the new drug application, the new antibiotic is permitted to be sold in the United States. At this point, a large effort is placed behind organizing the worldwide introduction of the new antimicrobial agent into the marketplace. This includes publication of a symposium (86, 155, 176 ) that reviews all of the relevant preclinical and clinical studies on the new agent. This type of peer review helps to support efforts to gain hospital formulary acceptance for the new agent. In today's highly competitive antibiotics marketplace, this is not an easy task. In order not to overburden the pharmacy budget of a hospital, acceptance of a new antibiotic onto the formulary often signals the discontinuation of an older agent. This is accomplished with great difficulty unless overwhelming published evidence documents the clinical efficacy, safety, convenience, or cost advantages of the new agent.
It is expected that the total scientific and medical information available describing a new antibiotic supports its use clinically. In this regard, basic information concerning the mechanism of antibacterial activity, human pharmacokinetic profile, and clinical efficacy all contribute to an understanding of the relative advantages of the new antimicrobial agent over existing therapy. The accuracy and thoroughness with which these studies are performed and their results disseminated to clinicians and other health care personnel are important factors in determining how well a new antibiotic will be accepted in this crowded therapeutic marketplace.
The remainder of this review will give an historical perspective on the discovery and development trends observed for certain classes of antibiotics. Some of the clinical and industrial influences that helped determine the direction of new antibiotic discovery and development will be discussed. The improvements made in specific antibiotics that supported their introduction into clinical practice will also be considered.
HISTORICAL TRENDS IN ANTIBIOTIC DISCOVERY AND DEVELOPMENT

Discovery of Penicillin G
The discovery of penicillin G (Fig. 6 ) marked the beginning of the modern antibiotic era and served as a model for the development of future agents in at least two ways. First, the isolation in 1957 of the active nucleus of penicillin G, 6 -aminopenicillanic acid (6-APA) (Fig. 6) , provided a key intermediate for production of a large number of new semisynthetic derivatives. The trend toward making chemical side chain substitutions around an active lead nucleus was subsequently followed for several other classes of betalactams, including the cephalosporins, carbapenems, penems, and monobactams. The second way in which penicillin G influenced antibiotic research resided in its ability to promote the spread of bacterial resistance genes that limited its own clinical effectiveness. The development of penicillin G was a result of pure necessity since the treatment of infectious diseases at that time was limited essentially to sulfonamides. Other penicillins, however, were later designed to combat resistance encountered from microbial elaboration of penicillinase.
The penicillins isolated from fermentation broths of Penicillium chrysogenum were found to be very active against gram-positive and gram-negative cocci. Upon its initial introduction in the early 1940s, over 85% of Staphylococcus aureus isolates were susceptible to <0.1 Vig of penicillin G per ml. However, penicillin-resistant staphylococci appeared within 3 years of the widespread use of this antimicrobial agent, and by 1948 up to 50% of hospital strains were resistant (51, 116, 131) . This trend continued as the level of resistance rose to 80% by 1957, the year that the structure of 6-APA was elucidated (131) . In 1944, Kirby identified the enzymatic mechanism responsible for penicillin resistance in bacteria (90) . When other agents such as erythromycin, chloramphenicol, and tetracyclines were chosen more frequently to treat penicillin-resistant staphylococci, bacterial resistance to these agents also increased, limiting their clinical use by the mid-1950s (92, 93) . Penicillin G also served as an alternative therapy for infections by Streptococcus pyogenes since, by the 1950s, resistance to tetracyclines and sulfonamides was common in this organism (50, 102, 129) . Despite the occasional isolation of resistant strains, pulmonary isolates of Streptococcus pneumoniae remain susceptible to penicillin G and synergy is still commonly demonstrated with penicillin G, in combination with aminoglycosides, against Enterococcus faecalis (43, 50) . With the appearance of sporadic sulfonamide resistance in Neisseria meningitidis in the 1960s, penicillin G was used empirically in suspected cases of meningitis (43, 116) . In the 1940s, isolates of N. gonorrhoeae demonstrated resistance to sulfonamides and penicillin G became the drug of choice. By 1975, however, the appearance of penicillinase-producing strains required the use of alternative therapies, including cefoxitin, spectinomycin, and tetracycline (175) .
Semisynthesis around 6-APA produced methicillin, oxacillin, nafcillin, and the cloxacillins, and the resistance of these compounds to inactivation by penicillinase earned them a prominent position in the treatment of staphylococcal infections. However, by 1961 the first methicillin-resistant strain of Staphylococcus aureus was isolated (84) and became a source of nosocomial infections in Europe in the 1960s and 1970s. This type of resistance was rare in the United States until the late 1970s (75, 163) . Methicillin- resistant staphylococci have increased in frequency steadily, yet they remain a nosocomial pathogen primarily at institutions such as large tertiary care hospitals and nursing homes with a large percentage of chronically ill patients (3, 163) . Strains that show intrinsic resistance to methicillin are also resistant to other beta-lactams and frequently contain additional resistance determinants for several other classes of antibiotics (3, 163) . The mechanism responsible for intrinsic methicillin resistance in staphylococci has been described in several reviews (23, 68, 96, 165) and involves the expression of PBP 2a, which has a lowered affinity for methicillin and other beta-lactams. Due to its activity against these organisms, vancomycin has become the agent of choice for clinical indications involving methicillin-resistant isolates (124) .
The development of penicillin for use against susceptible gram-positive and gram-negative cocci was a major advance in the treatment of infectious diseases when physicians had few agents from which to choose. Its broad use has been limited by the transfer among these pathogens of plasmidencoded penicillinases, a prime example of how quickly selective pressures from antibiotic use in the hospital can promote the spread of resistance. The trend toward development of resistance to penicillin G prompted research in the area of the penicillinase-stable penicillins and eventually to agents with a broader antibacterial spectrum.
Expanded-Spectrum Penicillins and the Aminoglycosides A major impact of the discovery of penicillin on the pharmaceutical industry was the subsequent successful use of 6-APA as a nucleus for the synthesis of many other new antibiotics. A natural extension of the synthetic chemistry work with 6-APA involved efforts to expand the spectrum of penicillin to include gram-negative bacilli. This was accomplished in 1961 with the introduction of the semisynthetic analog ampicillin. Ampicillin was effective against many enteric bacilli that did not elaborate high levels of betalactamase. Ampicillin also gained favor in the 1960s for the treatment of Haemophilus influenzae infections, since concerns over the hematological toxicities of chloramphenicol restricted its use. Plasmid-encoded beta-lactamase in H. influenzae was first noted in 1974, however (7, 164) , and by 1976 between 2 and 15% of isolates worldwide were resistant to ampicillin by this mechanism (47, 116, 144) .
The spectrum of penicillin derivatives was further expanded to include P. aeruginosa when carbenicillin was introduced in 1967 (131). This was followed by ticarcillin, and the novel ureido penicillins azlocillin, mezlocillin, and piperacillin were introduced in 1981. All of these agents had an extended spectrum of activity over ampicillin and carbenicillin, with piperacillin being the most potent agent against P. aeruginosa (45, 46, 72, 82, 108) . Thus, the trend for discovering penicillin derivatives up to this point has been to determine SAR that lead to development of molecules that are resistant to inactivation by beta-lactamases and that penetrate the outer membrane surrounding gram-negative cells. The trend toward development of broader-spectrum agents has continued with the aminoglycosides.
The aminoglycoside (aminocyclitol) antibiotics have had a major impact on the treatment of infectious diseases. Most clinically useful members of this class belong to the 4,6-disubstituted deoxystreptamine antibiotics of the kanamycin and gentamicin group (37) and are produced by members of the genus Streptomyces. Two of the best semisynthetic derivatives, amikacin and netilmicin, have been widely used clinically. The initial efforts in aminoglycoside research were directed toward discovery of potent compounds. In 1944, streptomycin was the first such agent (introduced for the treatment of tuberculosis) and it was followed by kanamycin in the 1950s, gentamicin in 1963, and tobramycin in 1968, all of which were used predominantly to treat serious infections with gram-negative bacilli (21, 37, 38, 172) . A number of factors have limited the introduction of new aminoglycosides, including their inherent potential to cause ototoxicity and nephrotoxicity. A large number of modifying enzymes have also been identified that spread among clinical isolates, limiting the antibacterial potency of these agents (35, 36, 81, 106, 126) . Aminoglycosides can be inactivated by more than 12 different classes of bacterial enzymes that can modify a reactive hydroxyl or amino group by phosphorylation, acetylation, or adenylylation (Fig. 6) . The 2"-adenylyltransferase, 6'-acetyltransferase, and 3-acetyltransferase enzymes are particularly prevalent among clinical strains in the United States (18) . With the rapid development of resistance to kanamycin that occurred in the late 1960s, this agent was replaced by gentamicin for empiric therapy of serious infections (44, 55) . The discovery of the aminoglycoside-modifying enzymes changed the direction of aminoglycoside research after the early 1960s. The development of new aminoglycosides followed a pattern aimed at identifying SAR that blocked susceptible sites for enzymatic modification on the molecule while retaining the acceptable safety profile of the earlier agents (9, 17) . While many new analogs were tested clinically (33, 126, 138) , amikacin remains one of the most useful due to the relatively infrequent occurrence of resistance encountered (13, 107) . Amikacin use was often restricted in many hospitals in hopes of preventing the emergence of resistant strains, but its use for empiric therapy in combination with beta-lactams has been widely adopted in centers where resistance to the older aminoglycosides is common.
The effort behind continued aminoglycoside development has largely been shifted to other classes of antimicrobial agents perceived to have a better safety profile and broader spectrum of activity against susceptible organisms. Despite the discovery of some new agents, it is generally believed that the incentive for research and development of aminoglycosides has reached its end (126 (Fig. 6 ) was in a large part a result of previous synthetic chemical expertise gained with 6-APA. As pointed out by G. N. Rolinson (131) , the removal of the side chain from cephalosporin C was necessary to produce the nucleus 7-aminocephalosporanic acid, the commercial starting material for synthesis of the semisynthetic cephalosporins (Fig. 6) The first semisynthetic cephalosporin developed for clinical use was cephalothin in 1962, followed 2 years later by cephaloridine. These compounds were followed by agents that were better tolerated upon injection, such as cefazolin, cephapirin, and cephacetrile, and the orally absorbed agents cephalexin, cefaclor, and cefadroxil. A major thrust of cephalosporin research was then aimed at expanding their antibacterial spectra by increasing their resistance to hydrolysis by beta-lactamase. The broader-spectrum compounds such as cefamandole, cefuroxime, and cefonicid possessed greater activity against the members of the family Enterobacteriaceae but often lost some activity against grampositive organisms (24, 137) . Perhaps the best representative of these agents was the novel cephamycin derivative cefoxitin (28, 89, 113, 114, 136, 153) . The improved resistance of this compound to beta-lactamase and the timing of its introduction into the marketplace established it as one of the most successful of the broader-spectrum agents. A similar cephamycin analog, cefotetan, possesses greater potency than cefoxitin against isolates of Enterobacter cloacae and Citrobacter freundii, although it is less potent against some gram-positive bacteria (118) .
The expanded-spectrum cephalosporins were distinguished from the earlier compounds based on the inclusion of P. aeruginosa in their activity spectra (137) . A great number of SAR have been determined with expandedspectrum cephalosporins, and these have been covered in several reviews (56, 117, 118, 137) . Cefotaxime and cefoperazone were among the first expanded-spectrum cephalosporins tested clinically, cefotaxime having a relatively high resistance to beta-lactamases and cefoperazone characterized by its good activity against P. aeruginosa (24, 85, 115, 147, 170) . In addition, the twice-daily dosing frequency achievable for cefoperazone presented an economic advantage over competitor compounds which required administration every 6 h (170). This improved dosing schedule occurred at a time when cost containment was becoming a major issue in health care. Another expanded-spectrum cephalosporin, moxalactam (Fig. 6) , is a structurally unique 1-oxocephalosporin containing an oxygen in place of sulfur at position 1 of the cephalosporin nucleus. This substitution confers high beta-lactamase resistance on the molecule (117) . Moxalactam use, however, was complicated by a relatively high incidence of a vitamin K-responsive coagulopathy, and this halted its use in the United States (88) .
Unlike the case with many of the preceding classes of antimicrobial agents, bacterial resistance to the expandedspectrum cephalosporins has not occurred to a high degree. This is due in part to their high affinity for lethal PBPs in the bacterial cell and their comparatively high resistance to inactivation by a broad variety of beta-lactamases. Problem organisms, however, include Enterobacter sp., Citrobacter sp., Serratia marcescens, and certain indole-positive Proteus sp., all of which produce chromosomally mediated cephalosporinase whose expression is under an inducible form of genetic regulation (70, 94, 95, 135, 160) . Under certain laboratory (and clinical) conditions, mutants that constitutively produce high levels of beta-lactamase can be selected upon exposure of the cells to cephalosporins (31, 69, 71) . The enzyme hydrolyzes the cephalosporin betalactam ring or simply binds the drug, impeding its progress across the periplasmic space to the lethal PBPs on the cytoplasmic membrane surface (67, 166 (22, 83, 130) .
Clavulanic acid and sulbactam are the most notable examples that have been introduced to improve the activity of amoxicillin and ampicillin, respectively, when used in combination against strains possessing plasmid-encoded betalactamases (22) . Monobactams are monocyclic beta-lactams that possess activity predominantly against gram-negative organisms, including P. aeruginosa (156, 159) . The (168) . These include BMY-28271, cefixime, FK-482, cefpodoxime, and the carbacephem analog of cefaclor (168) .
Some of the broadest-spectrum antibiotics have been derived from the carbapenem and penem structural classes. Penems are totally synthetic beta-lactams, while the carbapenems were derived from fermentation products, with thienamycin being the first member of the group identified (86, 151, 182) . Unlike carbapenems, the penems discovered to date lack activity against P. aeruginosa. Carbapenems such as imipenem also have an advantage over expandedspectrum cephalosporins in that they demonstrate high ac-VOL. 3, 1990 on January 18, 2018 by guest http://cmr.asm.org/ Downloaded from CLIN. MICROBIOL. REV. tivity against staphylococci, anaerobes, and almost all gramnegative bacilli, including P. aeruginosa (5, 86, 167) . The broad spectrum and potency are unprecedented compared with any other class of antibiotics, leading to broad clinical indications for imipenem (5, 169) . Several penem compounds have undergone clinical trials, but none has had the wide spectrum of imipenem. For reasons relating to unacceptable side effects, the remaining penems evaluated so far have not progressed to the marketplace (119, 122, 128, 182) . One of the drawbacks of carbapenems and penems is their unique susceptibility to degradation by eucaryotic renal dehydropeptidase I found in the brush borders of the kidney (86) . As described previously, imipenem was found to be so susceptible to dehydropeptidase I inactivation that an inhibitor of this enzyme, cilastatin, was developed for coadministration in order to stabilize the urinary metabolism of imipenem (86) . While the combination of imipenem-cilastatin has been widely used, research continues in an attempt to identify new agents of this class, such as SM-7338, that are potent antibacterial agents and have the added advantage of being resistant to destruction by the renal enzyme dehydropeptidase I.
The penems have also demonstrated another highly desirable characteristic, oral absorption. SCH-29482, FCE-22891, and SUN-5555 have shown relatively good oral absorption in humans (74, 168, 182) . This characteristic could result in a dual mode of dosing for these agents: an intravenous formulation for treating serious infections in the hospital and a less expensive oral formulation to be used as follow-up therapy once clinical improvement has occurred. While the first oral penem, SCH-29482, has not been developed for clinical use, it remains to be determined whether or not other agents of this interesting class will become successful products.
Quinolones
Quinolones are derivatives of nalidixic acid, which was first introduced in the 1960s. Historically, nalidixic acid (Fig.  6 ) has been reserved for use only in urinary tract infections due to its poor tissue distribution and the rapid emergence of bacterial resistance (59, 101) . Many new fluoroquinolone derivatives of nalidixic acid have been developed, and these compounds possess much greater antibacterial potency than the original compound. The primary target of the new fluoroquinolones in the bacterial cell is the A subunit of DNA gyrase; inhibition of gyrase function elicits a rapid bactericidal effect accompanied by induction of DNA repair responses (8, 29, 125, 148) . Since the A subunit of bacterial gyrase is a unique site of attack for these antimicrobial agents, many resistance mechanisms that have limited the susceptibility of bacteria to other agents do not affect susceptibility to quinolones. High-level resistance to the new quinolones has been observed but not with the same frequency as is characteristic for nalidixic acid (49) . These desirable characteristics, along with good oral absorption properties, have prompted continued efforts in the areas of synthetic quinolone research. Derivatives such as oxolinic acid, cinoxacin, and flumequine followed nalidixic acid but lacked sufficient antibacterial potency to be viewed as significant therapeutic advances. Flumequine (Fig. 6 ) was a breakthrough compound in synthesis efforts because it was the first analog to contain a fluorine in the quinolone nucleus. This change was found to impart improved spectrum and potency (174) and furthered efforts such as addition of active substituents (e.g., the piperazine moiety) on the fluoroquinolone nucleus, which in turn led to the discovery of the broader-spectrum agents in development today (30) . Nor- floxacin has been introduced recently as an orally active agent for urinary tract infections, but lacks the potency necessary for the treatment of serious systemic infections (176, 177) . More potent compounds such as fleroxacin, ofloxacin, enoxacin, and ciprofloxacin are markedly improved over the earlier quinolones and meet the criteria required for therapy of serious infections, including bacteremia, osteomyelitis, and pneumonia, as well as P. aeruginosa in cystic fibrosis patients (30, 40, 41, 171) . Perhaps the most useful property of the quinolones is their good oral absorption in humans. Ciprofloxacin is the broadest-spectrum, orally administered antibacterial agent developed. This compound fills a need for oral outpatient therapy of osteomyelitis and pulmonary infections associated with cystic fibrosis, as well as many other indications, and is available worldwide.
Even though a large number of fluoroquinolones have been synthesized and tested, the SAR needed for optimal antibacterial potency are not as well established as for other antibiotic classes such as the beta-lactams (30 
